Glycenil MR 60

Non-insulin-dependent diabetes (type 2) in adults when dietary measures, physical exercise & wt loss alone are not sufficient to control blood glucose.

Initially 30 mg daily, may be used for maintenance treatment if blood glucose is effectively controlled, or may be increased to 60 mg, 90 mg or 120 mg daily in successive steps if blood glucose is not adequately controlled. The interval between each dose increment should be at least 1 mth except in patients whose blood glucose has not reduced after 2 wk of treatment, whose dose may be increased at the end of the 2nd wk of treatment. Max daily dose: 120 mg. Switching from another oral antidiabetic agent to gliclazide Initially 30 mg, adjusted to suit patient's blood glucose response. Patient at risk of hypoglycemia Min daily starting dose: 30 mg.

Should be taken with food: Take as single intake at breakfast time. Swallow tab w/o crushing or chewing.

Hypersensitivity to gliclazide, other sulfonylurea or sulfonamides. Type 1 diabetes; diabetic pre-coma & coma, diabetic keto-acidosis. Concomitant use w/ miconazole. Severe renal or hepatic insufficiency. Lactation.

Hypoglycemia which may occur due to low-calorie diets, prolonged or strenuous exercise, alcohol intake, use in combination w/ other hypoglycemic agents, or presence of factors eg, patient refuses or, particularly for the elderly, is unable to cooperate, malnutrition, irregular mealtimes, skipping meals, periods of fasting or dietary changes, imbalance between physical exercise & carbohydrate intake, renal & severe hepatic insufficiency, overdose, thyroid disorders, hypopituitarism & adrenal insufficiency. St. John's wort prep, fever, trauma, infection or surgery may affect blood glucose control. Patients w/ G6PD deficiency. Porphyric patients. Inform patient of the importance of following dietary advice, taking regular exercise & regular monitoring of blood glucose levels. Carefully monitor blood glucose in concomitant use w/ a fluoroquinolone. Measurement of glycated Hb levels is recommended in assessing blood glucose control. Not to be administered to patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Caution in driving or operating machinery especially at the beginning of treatment due to symptoms of hypoglycemia. Avoid use during pregnancy. Safety & efficacy in childn & adolescents have not been established.

Hypoglycemia. Abdominal pain, nausea, vomiting, dyspepsia, diarrhea, constipation.

Increased hypoglycemic effect w/ miconazole; phenylbutazone; alcohol. Potentiation of blood glucose lowering effect & thus, in some instances, hypoglycemia may occur w/ other antidiabetic agents [eg, insulins, acarbose, biguanides (eg, metformin), thiazolidinediones, dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonists], β-blockers, fluconazole, ACE inhibitors (eg, captopril, enalapril), H₂-receptor antagonists, MAOIs, sulfonamides, clarithromycin & NSAIDs. Not recommended in combination w/ danazol. Increased blood glucose levels w/ chlorpromazine (high doses eg, >100 mg daily); ritodrine, salbutamol, terbutaline. Increased blood glucose levels w/ possible ketosis w/ glucocorticoids & tetracosactrin. Decreased exposure w/ St. John's wort prep. Risk of dysglycemia w/ fluoroquinolones. May lead to potentiation of anticoagulation during concurrent anticoagulant therapy eg, warfarin.

Antidiabetic Agents

A10BB09 - gliclazide ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.

Rx